BioCryst Pharmaceuticals reported $11.46M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
Chugai Pharma JPY 160.7B 53.18B Jun/2026
Daiichi Sankyo JPY 539.05B 57.81B Jun/2026
DBV Technologies USD 39.5M 1.44M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 7M Jun/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novavax USD 22.94M 6.84M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026